Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.43 |
| ▸ | NOS3 | P29474 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6630681 | 0.93 | NOS1 (0.52) | NOS1NOS3MEN1KMT2ACHRM2 | |
| SCHEMBL6622190 | 0.92 | NOS1 (0.42) | NOS1NOS3MEN1KMT2AMAPT | |
| SCHEMBL6630688 | 0.91 | NOS1 (0.43) | NOS1NOS3MEN1KMT2AMAPT | |
| SCHEMBL6630085 | 0.85 | NOS1 (0.50) | NOS1NOS3MEN1KMT2ACHRM2 | |
| SCHEMBL6650407 | 0.84 | NOS1 (0.51) | NOS1NOS3CHRM2CHRM4DRD2 | |
| SCHEMBL6619110 | 0.83 | NOS1 (0.41) | NOS1NOS3CHRM2CHRM4DRD2 | |
| SCHEMBL6618963 | 0.83 | NOS1 (0.41) | NOS1NOS3MEN1KMT2AMAPT | |
| SCHEMBL6620244 | 0.81 | NOS1 (0.39) | NOS1NOS3KMT2A | |
| SCHEMBL6630895 | 0.78 | NOS1 (0.46) | NOS1NOS3CHRM2CHRM4DRD2 | |
| SCHEMBL6632307 | 0.76 | NOS1 (0.60) | NOS1NOS3MEN1KMT2ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6235747-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC. | 2001-05-22 | — | — | US | claimed |
| EP-1471055-A1 | 6-phenylpyridyl-2-amine derivatives | PFIZER INC. (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1446405-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO | GPC Biotech Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003033499-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO | GPC BIOTECH INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| US-6465491-B2 | NITRIC OXIDE SYNTHASE INHIBITOR; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | LOWE JOHN A (US) | 2001-10-25 | — | — | US | disclosed |
| US-6235747-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | NOS2, NOS3, NOS1 | NOS1 3/4885NOS3 2/4885MEN1 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.